Tempus AI sued for allegedly misleading investors.

• Tempus AI faces class action lawsuit for securities law violations • Shareholders who purchased securities between Aug 6, 2024, and May 27, 2025, are encouraged to contact the firm • The company exaggerated the value of agreements and joint ventures, and acquired Ambry with a questionable reputation • Tempus made false and misleading statements to the market, leading to material falsehoods • The complaint alleges round-tripping funds to fabricate revenue in the joint venture with SoftBank.

Tempus AI, Inc. (NASDAQ: TEM), a technology company specializing in precision medicine through artificial intelligence, is facing a class action lawsuit for alleged securities law violations. The lawsuit, filed by investors, accuses the company of making false and misleading statements to the market, inflating the value of agreements, and engaging in questionable business practices.

Key Allegations:
The complaint alleges that Tempus AI exaggerated the value of several agreements, including transactions with affiliated entities and internally financed deals. The joint venture between Tempus and SoftBank Group Corporation was at risk due to the appearance of "round-tripping" funds to fabricate revenue. Additionally, Tempus acquired Ambry Genetics Corporation, which has a reputation for aggressive and potentially unethical business conduct. These circumstances led to material falsehoods in the company's public representations during the class period [1].

Investor Notification:
Investors who purchased Tempus securities between August 6, 2024, and May 27, 2025, are encouraged to contact the DJS Law Group, Robbins Geller Rudman & Dowd LLP, or Pomerantz LLP to discuss their rights. The deadline for investors to seek appointment as lead plaintiff in the lawsuit is August 12, 2025 [2][3].

Legal Proceedings:
The lawsuit, captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), charges Tempus AI and certain of its executives with violations of the Securities Exchange Act of 1934. The complaint alleges that Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins, and were self-funded. It also asserts that Tempus AI's joint venture with SoftBank and its acquisition of Ambry Genetics were at risk due to aggressive and potentially unethical business practices [2].

Market Impact:
On May 28, 2025, Spruce Point Capital Management issued a report on Tempus AI, raising numerous red flags over the company's management, operations, and financial reporting. This report led to a sharp decline in Tempus's stock price, falling more than 19% [2].

Legal Firms Involved:
Several prominent law firms are representing investors in this lawsuit. The DJS Law Group, Robbins Geller Rudman & Dowd LLP, and Pomerantz LLP are all involved in the case and have extensive experience in securities class actions and corporate governance litigation [1][2][3].

References:
[1] https://www.morningstar.com/news/pr-newswire/20250811la48188/tem-securities-lawsuit-filed-against-tempus-ai-inc-contact-the-djs-law-group-to-discuss-your-rights
[2] https://www.prnewswire.com/news-releases/investor-deadline-tomorrow-robbins-geller-rudman--dowd-llp-announces-that-tempus-ai-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit---tem-302525397.html
[3] https://www.morningstar.com/news/globe-newswire/9508234/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-tempus-ai-inc-of-class-action-lawsuit-and-upcoming-deadlines-tem